SCHEMBL2291344

SCHEMBL2291344

Cc1ccc(Br)c(CBr)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.39
FFAR4 Q5NUL3 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
AMY1A P0DUB6 1/20 0.36
ALDH1A1 P00352 6/20 0.36
CYP1A2 P05177 3/20 0.36
CYP2A6 P11509 2/20 0.36
TDP1 Q9NUW8 5/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPT P10636 5/20 0.34
HPGD P15428 3/20 0.34
THRB P10828 2/20 0.33
GPR55 Q9Y2T6 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30806439 1.00 TAAR1 (0.39) TAAR1FFAR4HTR2AHTR2CHTR2B
SCHEMBL27570578 0.82 TAAR1 (0.41) TAAR1FFAR4HTR2AHTR2CHTR2B
SCHEMBL30558293 0.81 HTR2A (0.41) TAAR1HTR2AHTR2CHTR2BALDH1A1
SCHEMBL4882598 0.81 GABRA1 (0.41) TAAR1FFAR4AMY1AALDH1A1CYP1A2
SCHEMBL3772270 0.81 HTR2A (0.41) TAAR1HTR2AHTR2CHTR2BALDH1A1
SCHEMBL17749069 0.80 ALOX15 (0.38) TAAR1FFAR4HTR2BAMY1AALDH1A1
SCHEMBL233314 0.80 TAAR1 (0.41) TAAR1HTR2AHTR2CHTR2BAMY1A
SCHEMBL2296290 0.80 FFAR4 (0.41) FFAR4HTR2AALDH1A1CYP1A2TDP1
SCHEMBL2790749 0.79 AMY1A (0.39) TAAR1FFAR4AMY1AALDH1A1CYP1A2
SCHEMBL13507390 0.79 TAAR1 (0.47) TAAR1FFAR4HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655291-A2 N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND Merck Sharp & Dohme LLC (US) 2025-12-03 EP disclosed
EP-4561561-A2 SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR Septerna, Inc. (US) 2025-06-04 EP disclosed
WO-2024158653-A2 N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS BACKGROUND MERCK SHARP & DOHME LLC (US) 2024-08-02 WO disclosed
WO-2024026076-A2 SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR SEPTERNA, INC. (US) 2024-02-01 WO disclosed
US-20230322675-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. 2023-10-12 US disclosed
WO-2023137634-A1 TRICYCLIC COMPOUND, PREPARATION THEREFOR, PHARMACEUTICAL COMPOSITION AND USE 上海奕拓医药科技有限责任公司 2023-07-27 WO disclosed
EP-3022202-B1 AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE NOVARTIS AG (CH) 2019-05-15 EP disclosed
US-10183025-B2 Autotaxin inhibitors NOVARTIS AG (CH) 2019-01-22 US disclosed
US-20180021345-A1 AUTOTAXIN INHIBITORS NOVARTIS AG (CH) 2018-01-25 US disclosed
CN-105555783-B Include the autotaxin inhibitors of heteroaromatic rings benzyl amide ring core 诺华股份有限公司 2017-12-01 CN disclosed
US-20160024123-A1 Asymmetrical Ligands BOREALIS AG (AT) 2016-01-28 US disclosed
US-9187583-B2 Catalysts BOREALIS AG (AT) 2015-11-17 US disclosed
WO-2015008230-A1 AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE NOVARTIS AG (CH) 2015-01-22 WO disclosed
US-20140221584-A1 CATALYSTS BOREALIS AG (AT) 2014-08-07 US disclosed
WO-2013010880-A1 NEW CRTH2 ANTAGONISTS ALMIRALL, S.A. (ES) 2013-01-24 WO disclosed
US-7994367-B2 Method for producing benzaldehyde compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20100210879-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-08-19 US disclosed
US-20100087669-A1 NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-04-08 US disclosed
EP-1474414-B1 DIHYDRO-THIA-PHENANTHRENE-CARBONYL-GUANIDINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC REAGENT SANOFI AVENTIS DEUTSCHLAND (DE) 2007-12-12 EP disclosed
US-20070015931-A1 Novel phenylboronic acid compounds and intermediates and processes for the preparation thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322675-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR2, LPAR1, LPAR6 TAAR1 824/4885FFAR4 88/4885HTR2A 635/4885
US-20070015931-A1 Novel phenylboronic acid compounds and intermediates and processes for the preparation thereof VDR, CYP24A1, CYP2R1 TAAR1 3486/4885FFAR4 276/4885HTR2A 4702/4885
US-20100210879-A1 METHOD FOR PRODUCING BENZALDEHYDE COMPOUND NQO1, C9, TRPA1 TAAR1 2679/4885FFAR4 3092/4885HTR2A 667/4885
US-20180021345-A1 AUTOTAXIN INHIBITORS ENPP2, SERPINB1, TFPI TAAR1 3932/4885FFAR4 4254/4885HTR2A 2642/4885
US-20160024123-A1 Asymmetrical Ligands CCRL2, AR, CCR2 TAAR1 601/4885FFAR4 2022/4885HTR2A 643/4885
US-10183025-B2 Autotaxin inhibitors ENPP2, SERPINB1, TFPI TAAR1 3932/4885FFAR4 4254/4885HTR2A 2642/4885
US-20100087669-A1 NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF VDR, CYP24A1, CYP2R1 TAAR1 3486/4885FFAR4 276/4885HTR2A 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.